EXTRAWELL PHAR (00858) announced its annual performance. The shareholders are expected to have a loss of about 980 million Hong Kong dollars, compared to a profit in the previous year.
Jingyou Pharmaceutical (00858) announced its operating revenue for the year ending March 31, 2026, at approximately 51.481 million Hong Kong dollars, a decrease of 7.12% year-on-year. The net loss attributable to the company's owners is approximately 980 million Hong Kong dollars, a change from profit to loss compared to the previous year. The loss per share is 39.52 Hong Kong cents.
EXTRAWELL PHAR (00858) announced its annual performance for the year ending March 31, 2026, with a revenue from continuing operations of approximately HK$51.48 million, a decrease of 7.12% year-on-year. The company's attributable loss was around HK$980 million, a turnaround from a profit to a loss. The loss per share was 39.52 HK cents.
Related Articles
COSCO SHIPPING Development(02866) plans to invest 8.656 billion yuan to acquire a total of 24 vessels.
REALWAY CAPITAL(01835): Change of controlling shareholder, offering a cash offer of approximately 39.39% discount and will resume trading on July 2nd.
HUNLICAR GROUP (03638) announced its annual performance, with a net profit attributable to shareholders of HK$28.166 million.
COSCO SHIPPING Development(02866) plans to invest 8.656 billion yuan to acquire a total of 24 vessels.
REALWAY CAPITAL(01835): Change of controlling shareholder, offering a cash offer of approximately 39.39% discount and will resume trading on July 2nd.
HUNLICAR GROUP (03638) announced its annual performance, with a net profit attributable to shareholders of HK$28.166 million.
RECOMMEND
